Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Press Release
Article
Camber Pharmaceuticals Launches Generic Xeloda®
Key Takeaways
- Capecitabine Tablets, USP, are now part of Camber Pharmaceuticals' product offerings, targeting multiple cancer types.
- Indications include colorectal, breast, gastric, esophageal, gastroesophageal junction, and pancreatic cancers.
Camber Pharmaceuticals is excited to announce the addition of Capecitabine Tablets, USP, to our product portfolio. Capecitabine is a nucleoside metabolic inhibitor indicated for the treatment of several cancers, including:
- Colorectal Cancer
- Breast Cancer
- Gastric, Esophageal, or Gastroesophageal Junction Cancer
- Pancreatic Cancer
For more information about these indications, please visit our website: www.camberpharma.com/capecitabine. Capecitabine Tablets, USP are available in the following strengths and packaging options:
- 150 mg – 60 count bottles
- 500 mg – 60 count and 120 count bottles
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Videos
Related Content
